Non-invasive quantum sensing for continuous glucose monitoring

该项目的目标是对代号为LUX1的第二代量子传感器进行体外可行性研究，该传感器以革命性的新方式光学监测葡萄糖。与目前可用的传感器不同，LUX1将允许糖尿病患者（PLWD）方便地测量实时葡萄糖水平，而无需抽血或破坏皮肤表面，只需将手指或手腕与设备接触即可。LUX1的愿景最初是一个即时护理设备，我们的目标是将其扩展为智能手表般的可穿戴设备，例如，Apple Watch，与当前在一台设备上测量多个生命体征的趋势保持一致。我们的创新方法将有助于解决一个重大的全球性问题。目前，全球约有4.63亿糖尿病患者，预计在未来25年内将增加到7亿，另有数百万未确诊病例。糖尿病显著降低预期寿命-I型糖尿病平均降低20年以上，II型糖尿病平均降低10年。在英国，每周约有500例过早死亡，NHS将年度预算的10%用于糖尿病及其并发症的治疗，相当于每年100亿英镑（或每周1.92亿英镑）的支出。尽管情况越来越严重，但许多人仍然使用侵入性的、不可重复使用的和不具成本效益的方法来监测葡萄糖。这表明迫切需要下一代血糖监测仪，如LUX1，以帮助PLWD/医疗保健专业人员在糖尿病管理中更加积极主动，以减少截肢/过早死亡的数量和相关成本。为了开发我们的LUX1原型，我们将项目分为四个工作包：* 业务开发 * 传感器设计/制造 * 传感器包装/测试 * 体外可行性研究

The objective of the project is to conduct in-vitro feasibility studies for a second- generation quantum sensor, codenamed LUX1, that optically monitors glucose in a revolutionary new way. Unlike currently available sensors, LUX1 will allow people living with diabetes (PLWD) to conveniently measure real-time glucose levels without drawing blood or breaking the skin surface, simply by bringing their finger or wrist into contact with the device. The vision for LUX1 is initially a point- of-care device and we aim to miniaturise it into a smartwatch-like wearable, e.g., Apple watch, aligning with current trends of measuring multiple vitals all in one device.Our innovative approach will be instrumental in tackling a significant worldwide problem. Currently, there are around 463M diabetes sufferers worldwide and this is predicted to rise to 700M over the next 25 years, with millions of additional undiagnosed cases. Diabetes significantly reduces life expectancy -- Type I on average by more than 20 years, and up to 10 years for Type II. In the UK, there are around 500 premature deaths every week and the NHS spend 10% of the annual budget contributing to the treatment of diabetes and the complications, equating to an expenditure of £10B per year (or £192M per week). Despite the growing severity of the situation, many people are still using invasive, non- reusable and non-cost-effective methods to monitor glucose. This demonstrates a compelling need for next-generation glucose monitors, like LUX1, to help PLWD/healthcare professionals to be more proactive in diabetes management to reduce the number of amputations/premature deaths, and associated costs.To develop our LUX1 prototype, we have split the project into four work packages:* Business development* Sensor design/manufacture* Sensor packaging/testing* In-vitro feasibility studies